Neuropeptides: opportunities for drug discovery

The role of peptides as signalling molecules in the nervous system has been studied for more than 30 years. Neuropeptides and their G-protein-coupled receptors are widely distributed throughout the body and they commonly occur with, and are complementary to, classic neurotransmitters. The functions of neuropeptides range from neurotransmitter to growth factor. They are present in glial cells, are hormones in the endocrine system, and are messengers in the immune system. Much evidence indicates that neuropeptides are of particular importance when the nervous system is challenged (eg, by stress, injury, or drug abuse). These features and the large number of neuropeptides and neuropeptide receptors provide many opportunities for the discovery of new drug targets for the treatment of nervous-system disorders. In fact, receptor-subtype-selective antagonists and agonists have been developed, and recently a substance P receptor (neurokinin 1) antagonist has been shown to have clinical efficacy in the treatment of major depression and chemotherapy-induced emesis. Several other neuropeptide receptor ligands are in clinical trials for various indications.

[1]  W. Rostène,et al.  Nonpeptide antagonists of neuropeptide receptors: tools for research and therapy. , 1997, Trends in pharmacological sciences.

[2]  L. Muglia,et al.  Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need , 1995, Nature.

[3]  T. Hökfelt,et al.  Galanin and spinal nociceptive mechanisms: recent advances and therapeutic implications , 2000, Neuropeptides.

[4]  Eric R. Kandel,et al.  Identification of a Signaling Network in Lateral Nucleus of Amygdala Important for Inhibiting Memory Specifically Related to Learned Fear , 2002, Cell.

[5]  J. Hohmann,et al.  Pediatrics, and , 2022 .

[6]  Marc Parmentier,et al.  Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor , 1995, Nature.

[7]  N. Rothwell,et al.  Hypothalamic control of feeding , 1999, Current Opinion in Neurobiology.

[8]  Ji-Sheng Han,et al.  Acupuncture: neuropeptide release produced by electrical stimulation of different frequencies , 2003, Trends in Neurosciences.

[9]  K. Fuxe,et al.  Increased density of galanin binding sites in the dorsal raphe in a genetic rat model of depression , 2002, Neuroscience Letters.

[10]  N. Ramsey,et al.  Endogenous opioids and reward. , 2000, European journal of pharmacology.

[11]  J. Halaas,et al.  Leptin and the regulation of body weight in mammals , 1998, Nature.

[12]  P. Mantyh,et al.  Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. , 1997, Science.

[13]  Thomas R Insel,et al.  Neuropeptides and the evolution of social behavior , 2000, Current Opinion in Neurobiology.

[14]  Neurobiology: Fear thou not , 2003, Nature.

[15]  C. Nemeroff New directions in the development of antidepressants: the interface of neurobiology and psychiatry , 2002, Human psychopharmacology.

[16]  G. Siggins,et al.  Somatostatin depresses excitatory but not inhibitory neurotransmission in rat CA1 hippocampus. , 1997, Journal of neurophysiology.

[17]  C. Nemeroff Psychopharmacology of affective disorders in the 21st century. , 1998, Biological psychiatry.

[18]  H. Grill,et al.  The Neuroanatomical Axis for Control of Energy Balance , 2002, Frontiers in Neuroendocrinology.

[19]  T. Hökfelt,et al.  Hypothalamic and vagal neuropeptide circuitries regulating food intake , 2001, Physiology & Behavior.

[20]  S. Nakanishi,et al.  The protein-coding sequence of the bovine ACTH-β-LPH precursor gene is split near the signal peptide region , 1980, Nature.

[21]  A. Simon,et al.  Deletion of CCK2 Receptor in Mice Results in an Upregulation of the Endogenous Opioid System , 2002, The Journal of Neuroscience.

[22]  T. Taniwaki,et al.  Heterogeneity of expression of neuropeptide genes by astrocytes: functional implications. , 1994, Perspectives on developmental neurobiology.

[23]  Emmanuel Mignot,et al.  The Sleep Disorder Canine Narcolepsy Is Caused by a Mutation in the Hypocretin (Orexin) Receptor 2 Gene , 1999, Cell.

[24]  R Guillemin,et al.  Peptides in the brain: the new endocrinology of the neuron. , 1978, Science.

[25]  M. Kuhar,et al.  CART peptides: novel addiction- and feeding-related neuropeptides , 1999, Trends in Neurosciences.

[26]  D. Naber,et al.  Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. , 2003, Archives of general psychiatry.

[27]  B. Roques,et al.  Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. , 1995, NIDA research monograph.

[28]  F. Marshall,et al.  RAMPs: accessory proteins for seven transmembrane domain receptors. , 1999, Trends in pharmacological sciences.

[29]  J. Stewart,et al.  Role of Tachykinins in the Host Response to Murine Gammaherpesvirus Infection , 2001, Journal of Virology.

[30]  John C. Eccles,et al.  Chapter 1 Chemical transmission and Dale's principle , 1986 .

[31]  D. Grandy,et al.  Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor , 1995, Science.

[32]  G. Sperk,et al.  Neuropeptide Y: emerging evidence for a functional role in seizure modulation , 1999, Trends in Neurosciences.

[33]  T. Hökfelt,et al.  The participation of galanin in pain processing at the spinal level. , 2002, Trends in pharmacological sciences.

[34]  B. Roos,et al.  Identification of a protein that confers calcitonin gene-related peptide responsiveness to oocytes by using a cystic fibrosis transmembrane conductance regulator assay. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  F. Lembeck Zur Frage der zentralen Übertragung afferenter Impulse , 2004, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[36]  Michel Bouvier,et al.  Oligomerization of G-protein-coupled transmitter receptors , 2001, Nature Reviews Neuroscience.

[37]  T. Theoharides Mast cells and stress--a psychoneuroimmunological perspective. , 2002, Journal of clinical psychopharmacology.

[38]  T. Hökfelt,et al.  Suppressed kindling epileptogenesis in mice with ectopic overexpression of galanin , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[39]  B. Rounsaville,et al.  Naltrexone and coping skills therapy for alcohol dependence. A controlled study. , 1992, Archives of general psychiatry.

[40]  D. Banville,et al.  Proenkephalin A gene products activate a new family of sensory neuron–specific GPCRs , 2002, Nature Neuroscience.

[41]  P. Greengard The neurobiology of slow synaptic transmission. , 2001, Science.

[42]  R. Palmiter,et al.  Knock-Out Mice Reveal a Critical Antiepileptic Role for Neuropeptide Y , 1997, The Journal of Neuroscience.

[43]  E. Kandel The Molecular Biology of Memory Storage: A Dialogue Between Genes and Synapses , 2001, Science.

[44]  W. Colmers,et al.  Effects of neuropeptide Y on the electrical properties of neurons , 1994, Trends in Neurosciences.

[45]  Q. Pittman,et al.  Talking back: dendritic neurotransmitter release , 2003, Trends in Neurosciences.

[46]  Clifford B. Saper,et al.  Unraveling the central nervous system pathways underlying responses to leptin , 1998, Nature Neuroscience.

[47]  J. Lauterborn,et al.  Focal hippocampal lesions induce seizures and long-lasting changes in mossy fiber enkephalin and CCK immunoreactivity , 1988, Peptides.

[48]  T. Hökfelt,et al.  Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. , 1999, Neuroreport.

[49]  D. Payan,et al.  Delineation of the endocytic pathway of substance P and its seven-transmembrane domain NK1 receptor. , 1995, Molecular biology of the cell.

[50]  K. Kangawa,et al.  Ghrelin and the regulation of food intake and energy balance. , 2002, Molecular interventions.

[51]  G. Cottrell The first peptide-gated ion channel. , 1997, The Journal of experimental biology.

[52]  O. Civelli,et al.  Novel neurotransmitters as natural ligands of orphan G-protein-coupled receptors , 2001, Trends in Neurosciences.

[53]  G. Coukos,et al.  Corticotropin-releasing hormone promotes blastocyst implantation and early maternal tolerance , 2001, Nature Immunology.

[54]  Jon T. Willie,et al.  To eat or to sleep? Orexin in the regulation of feeding and wakefulness. , 2001, Annual review of neuroscience.

[55]  M. Kramer Clinical update: substance P antagonists in patients with major depression , 2002, European Psychiatry.

[56]  J. P. Schwartz Neurotransmitters as neurotrophic factors: a new set of functions. , 1992, International review of neurobiology.

[57]  A. Alterman,et al.  Naltrexone in the treatment of alcohol dependence. , 1992, Archives of general psychiatry.

[58]  Michael Costigan,et al.  Replicate high-density rat genome oligonucleotide microarrays reveal hundreds of regulated genes in the dorsal root ganglion after peripheral nerve injury. , 2002, BMC Neuroscience.

[59]  B. Mellström,et al.  Protein Kinase A-Dependent Derepression of the Human Prodynorphin Gene via Differential Binding to an Intragenic Silencer Element , 1998, Molecular and Cellular Biology.

[60]  S. Leibowitz Brain peptides and obesity: pharmacologic treatment. , 1995, Obesity research.

[61]  M Morfis,et al.  Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. , 1999, Molecular pharmacology.

[62]  D. Wied Behavioral pharmacology of neuropeptides related to melanocortins and the neurohypophyseal hormones. , 1999 .

[63]  E. Butelman,et al.  Pharmacotherapy of addictions , 2002, Nature Reviews Drug Discovery.

[64]  G. Griebel,et al.  Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[65]  S. Iversen,et al.  The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. , 1990, European journal of pharmacology.

[66]  J. Drews Drug discovery: a historical perspective. , 2000, Science.

[67]  M. Lazdunski,et al.  Cloning of the amiloride-sensitive FMRFamide peptide-gated sodium channel , 1995, Nature.

[68]  C. Wahlestedt,et al.  Expression of the novel galanin receptor subtype GALR2 in the adult rat CNS: Distinct distribution from GALR1 , 1999, The Journal of comparative neurology.

[69]  Y. Hurd,et al.  Reduced neuropeptide Y mRNA expression in the prefrontal cortex of subjects with bipolar disorder. , 1999, Neuroreport.

[70]  P. Bolton,et al.  Autism and multiple exostoses associated with an X;8 translocation occurring within the GRPR gene and 3' to the SDC2 gene. , 1997, Human molecular genetics.

[71]  J. Olesen,et al.  Cgrp May Play A Causative Role in Migraine , 2002, Cephalalgia : an international journal of headache.

[72]  T. Moran,et al.  Cholecystokinin and satiety: current perspectives. , 2000, Nutrition.

[73]  R. Palmiter,et al.  Ethanol consumption and resistance are inversely related to neuropeptide Y levels , 1998, Nature.

[74]  E. B. Souza Corticotropin-releasing factor receptors: Physiology, pharmacology, biochemistry and role in central nervous system and immune disorders , 1995, Psychoneuroendocrinology.

[75]  T. Hökfelt,et al.  Hypothalamic neurohistochemistry of the murine anorexia (anx/anx) mutation: Altered processing of neuropeptide Y in the arcuate nucleus , 1997, The Journal of comparative neurology.

[76]  Sebastiaan Overeem,et al.  A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains , 2000, Nature Medicine.

[77]  K. Blennow,et al.  Differences in the neuropeptide Y-like immunoreactivity of the plasma and platelets of human volunteers and depressed patients , 1996, Peptides.

[78]  F. Strand,et al.  Neuropeptide hormones as neurotrophic factors. , 1991, Physiological reviews.

[79]  T. Hökfelt,et al.  Expression and localization of gastrin messenger RNA and peptide in spermatogenic cells. , 1990, The Journal of clinical investigation.

[80]  S. Hunt,et al.  Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation , 1999 .

[81]  S. Nakanishi,et al.  cDNA eloping of bovine substance-K receptor through oocyte expression system , 1987, Nature.

[82]  I. Whishaw,et al.  DREAM Is a Critical Transcriptional Repressor for Pain Modulation , 2002, Cell.

[83]  A. Schally Aspects of hypothalamic regulation of the pituitary gland. , 1978, Science.

[84]  J. Sutcliffe,et al.  The hypocretins: Setting the arousal threshold , 2002, Nature Reviews Neuroscience.

[85]  J. Roberts,et al.  Characterization of a common precursor to corticotropin and beta-lipotropin: identification of beta-lipotropin peptides and their arrangement relative to corticotropin in the precursor synthesized in a cell-free system. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[86]  Robert J. Lefkowitz,et al.  Classical and new roles of β-arrestins in the regulation of G-PROTEIN-COUPLED receptors , 2001, Nature Reviews Neuroscience.

[87]  J P Vincent,et al.  Neurotensin and neurotensin receptors. , 1999, Trends in pharmacological sciences.

[88]  Massimo Rizzi,et al.  Neuropeptides-immunoreactivity and their mRNA expression in kindling: functional implications for limbic epileptogenesis , 1996, Brain Research Reviews.

[89]  Masao Ito,et al.  Corticotropin-Releasing Factor Plays a Permissive Role in Cerebellar Long-Term Depression , 1999, Neuron.

[90]  C. Heyser,et al.  Animal models of motivation for drinking in rodents with a focus on opioid receptor neuropharmacology. , 2003, Recent developments in alcoholism : an official publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism.

[91]  M S Kramer,et al.  Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. , 1999, Trends in pharmacological sciences.

[92]  C. Gall,et al.  Kainic acid-induced seizures stimulate increased expression of nerve growth factor mRNA in rat hippocampus. , 1991, Brain research. Molecular brain research.

[93]  Michael Aldrich,et al.  Reduced Number of Hypocretin Neurons in Human Narcolepsy , 2000, Neuron.

[94]  L. Swanson,et al.  Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing , 1983, Nature.

[95]  E. Theodorsson,et al.  Neuropeptide Y, neurokinin A and neurotensin in brain regions of Fawn Hooded “depressed”, wistar, and Sprague dawley rats. Effects of electroconvulsive stimuli , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[96]  Stephen P. Hunt,et al.  Altered nociception, analgesia and aggression in mice lacking the receptor for substance P , 1998, Nature.

[97]  Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. , 2002, Current opinion in investigational drugs.

[98]  I. Kupfermann Functional studies of cotransmission. , 1991, Physiological reviews.

[99]  R G Hill,et al.  Distinct mechanism for antidepressant activity by blockade of central substance P receptors. , 1998, Science.

[100]  F. Holsboer,et al.  Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. , 2000, Journal of psychiatric research.

[101]  D. Gerhold,et al.  Chronic neuropathic pain is accompanied by global changes in gene expression and shares pathobiology with neurodegenerative diseases , 2002, Neuroscience.

[102]  F E Bloom,et al.  The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[103]  G. Dechant,et al.  Therapy of neurodegenerative diseases using neurotrophic factors: cell biological perspective , 2002, Expert review of neurotherapeutics.

[104]  R. Freidinger,et al.  Nonpeptidic ligands for peptide and protein receptors. , 1999, Current opinion in chemical biology.

[105]  A. Sweet-Cordero,et al.  Dale's hypothesis revisited: different neuropeptides derived from a common prohormone are targeted to different processes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[106]  K. Fuxe,et al.  Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment. , 1998, Brain research. Molecular brain research.

[107]  L. Terenius,et al.  Acquisition, Expression, and Reinstatement of Ethanol-Induced Conditioned Place Preference in Mice: Effects of Opioid Receptor-Like 1 Receptor Agonists and Naloxone , 2003, Journal of Pharmacology and Experimental Therapeutics.

[108]  T. Hökfelt,et al.  Activation of Delta Opioid Receptors Induces Receptor Insertion and Neuropeptide Secretion , 2003, Neuron.

[109]  S. Carr,et al.  Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate Feeding Behavior , 1998, Cell.

[110]  A. Basbaum,et al.  Resistance to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin A gene. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[111]  T. Foroud,et al.  A quantitative trait locus for alcohol consumption in selectively bred rat lines. , 1998, Alcoholism, clinical and experimental research.

[112]  C. Gaveriaux-Ruff,et al.  Exploring the opioid system by gene knockout , 2002, Progress in Neurobiology.

[113]  A Carlsson,et al.  A Paradigm Shift in Brain Research , 2001, Science.

[114]  P. Ernfors,et al.  Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor , 2001, Nature.

[115]  R. Stevenson,et al.  AGTR2 Mutations in X-Linked Mental Retardation , 2002, Science.

[116]  M. Palkovits,et al.  Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[117]  Patrick D. Wall,et al.  Pain mechanisms: A new theory , 1996 .

[118]  Markus Heilig,et al.  Brain Neuropeptide Υ (NPY) in Stress and Alcohol Dependence , 2002 .

[119]  Walter Born,et al.  An Amylin Receptor Is Revealed Following Co-Transfection of a Calcitonin Receptor with Receptor Activity Modifying Proteins-1 or -3. , 1999, Endocrinology.

[120]  E. Marder,et al.  The roles of co-transmission in neural network modulation , 2001, Trends in Neurosciences.

[121]  T. Hökfelt,et al.  Anticonvulsant activity of a nonpeptide galanin receptor agonist , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[122]  H. Morris,et al.  Calcitonin gene-related peptide is a potent vasodilator , 1985, Nature.

[123]  Sebastiaan Overeem,et al.  Hypocretin (orexin) deficiency in human narcolepsy , 2000, The Lancet.

[124]  Lan Bao,et al.  Identification of gene expression profile of dorsal root ganglion in the rat peripheral axotomy model of neuropathic pain , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[125]  F. Holsboer,et al.  The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. , 1999, Journal of psychiatric research.

[126]  Rachel L. Batterham,et al.  Gut hormone PYY3-36 physiologically inhibits food intake , 2002, Nature.

[127]  T. Renda,et al.  The brain-gut-skin triangle: New peptides , 1981, Peptides.

[128]  M. T. Koh,et al.  Voluntary Alcohol Consumption Is Controlled via the Neuropeptide Y Y1 Receptor , 2002, The Journal of Neuroscience.

[129]  S. Snyder,et al.  Atypical neural messengers , 2001, Trends in Neurosciences.

[130]  J M Bidlack,et al.  An all D-amino acid opioid peptide with central analgesic activity from a combinatorial library. , 1994, Science.

[131]  F. Holsboer,et al.  Enhanced and Delayed Stress-Induced Alcohol Drinking in Mice Lacking Functional CRH1 Receptors , 2002, Science.

[132]  J. Penninger,et al.  Transcriptional mechanisms underlying neuropathic pain: DREAM, transcription factors and future pain management? , 2002, Expert review of neurotherapeutics.

[133]  Melanie G. Lee,et al.  RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor , 1998, Nature.

[134]  A. Inui Feeding and body-weight regulation by hypothalamic neuropeptides—mediation of the actions of leptin , 1999, Trends in Neurosciences.

[135]  T. Hökfelt,et al.  Differential regulation of mRNAs for neuropeptide Y and its receptor subtypes in widespread areas of the rat limbic system during kindling epileptogenesis. , 1999, Brain research. Molecular brain research.

[136]  J. Shine,et al.  Critical role for GALR1 galanin receptor in galanin regulation of neuroendocrine function and seizure activity. , 2002, Brain research. Molecular brain research.

[137]  D. Macneil,et al.  Neither Agouti-Related Protein nor Neuropeptide Y Is Critically Required for the Regulation of Energy Homeostasis in Mice , 2002, Molecular and Cellular Biology.

[138]  S. Woods,et al.  Signals that regulate food intake and energy homeostasis. , 1998, Science.

[139]  L. Maltais,et al.  Anorexia, a recessive mutation causing starvation in preweanling mice. , 1984, The Journal of heredity.

[140]  T. Hökfelt,et al.  Altered Hippocampal Expression of Neuropeptides in Seizure‐prone GALR1 Knockout Mice , 2003, Epilepsia.

[141]  G. M. Halliday,et al.  Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus , 1991, Neuroscience.

[142]  F E Bloom,et al.  Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional tag PCR subtraction. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[143]  E. Gibson,et al.  Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. , 1997, TIPS - Trends in Pharmacological Sciences.

[144]  Jon T. Willie,et al.  Narcolepsy in orexin Knockout Mice Molecular Genetics of Sleep Regulation , 1999, Cell.

[145]  R. Palmiter,et al.  Life without neuropeptide Y. , 1998, Recent progress in hormone research.

[146]  S. Itoh,et al.  Caerulein and cholecystokinin suppress β-endorphin-induced analgesia in the rat , 1982 .

[147]  P. Goadsby,et al.  Vasoactive peptide release in the extracerebral circulation of humans during migraine headache , 1990, Annals of neurology.

[148]  C. Epstein,et al.  Primary afferent tachykinins are required to experience moderate to intense pain , 1998, Nature.

[149]  L. Watkins,et al.  Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. , 1983, Science.

[150]  H. Hashimoto,et al.  Plasma neuropeptide Y in patients with major depressive disorder , 1996, Neuroscience Letters.

[151]  C. Peyron,et al.  The hypocretin/orexin ligand–receptor system: implications for sleep and sleep disorders , 2000, Trends in Neurosciences.